Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 27:11:583182.
doi: 10.3389/fneur.2020.583182. eCollection 2020.

Extended Study of NUS1 Gene Variants in Parkinson's Disease

Lamei Yuan  1 , Xiangyu Chen  1 , Zhi Song  2 , Weidong Le  3 , Wen Zheng  2 , Xin Liu  1 , Hao Deng  1   2
Affiliations

Extended Study of NUS1 Gene Variants in Parkinson's Disease

Lamei Yuan et al. Front Neurol. .

Abstract

Parkinson's disease (PD), is the second most common neurodegenerative disorder worldwide. Genetic, environmental factors, and aging are its primary development contributors. Recently the nuclear undecaprenyl pyrophosphate synthase 1 homolog (Saccharomyces cerevisiae) gene (NUS1) was reported as a candidate gene for PD, which raised our interest in the relationship between NUS1 and PD. This study was aimed to further explore the role of NUS1 variants in PD development. Genetic analysis for 308 Han-Chinese PD patients and 308 ethnically matched controls using whole exome sequencing was conducted. Additionally, a total of 60 articles involving in whole exome/whole genome sequencing or direct sequencing of the NUS1 gene from PubMed database between July 1, 2011 and August 26, 2020 were reviewed to evaluate PD-associated NUS1 variants. No potentially pathogenic NUS1 variant was found in 308 PD cases, and no frequency biases between 308 PD cases and 308 controls were observed for the only non-synonymous variant p.Asp179Glu (genotype: χ2 = 0.093, P = 0.761; allele: χ2 = 0.092, P = 0.762). No pathogenic or disease-associated NUS1 variant was reported in the 5,636 PD cases of the 60 articles. In summary, current findings indicate that NUS1 variant is not a common genetic factor contributing to PD.

Keywords: NUS1; Parkinson's disease; genetic analysis; whole exome sequencing; whole genome sequencing.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • NUS1 and Epilepsy-myoclonus-ataxia Syndrome: An Under-recognized Entity?
    Riboldi GM, Monfrini E, Stahl C, Frucht SJ. Riboldi GM, et al. Tremor Other Hyperkinet Mov (N Y). 2022 Jun 15;12:21. doi: 10.5334/tohm.696. eCollection 2022. Tremor Other Hyperkinet Mov (N Y). 2022. PMID: 35949226 Free PMC article.
  • Lysosomal cholesterol accumulation contributes to the movement phenotypes associated with NUS1 haploinsufficiency.
    Yu SH, Wang T, Wiggins K, Louie RJ, Merino EF, Skinner C, Cassera MB, Meagher K, Goldberg P, Rismanchi N, Chen D, Lyons MJ, Flanagan-Steet H, Steet R. Yu SH, et al. Genet Med. 2021 Jul;23(7):1305-1314. doi: 10.1038/s41436-021-01137-6. Epub 2021 Mar 17. Genet Med. 2021. PMID: 33731878 Free PMC article.
  • The Progression of NUS1-Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR.
    Li L, Huang J, Xiang Y, Zhang X, Xu Q, Sun Q, Liu Z, Yan X, Li J, Tang B, Guo J. Li L, et al. CNS Neurosci Ther. 2025 Jul;31(7):e70549. doi: 10.1111/cns.70549. CNS Neurosci Ther. 2025. PMID: 40726114 Free PMC article.
  • The Spectrum of Neurologic Phenotypes Associated With NUS1 Pathogenic Variants: A Comprehensive Case Series.
    Brooker SM, Novelli M, Coukos R, Prakash N, Kamel WA, Amengual-Gual M, Anheim M, Barcia G, Bardakjian T, Baur F, Berweck S, Bölsterli BK, Brugger M, Cassini T, Chatron N, Corner B, Dafsari HS, de Sainte Agathe JM, Ellis CA, Ezell KM, Foucard C, Frucht SJ, Garcia MC, Gill D, Guimier A, Hamid R, Heine-Suñer D, Herkenrath P, Hully M, Isaias IU, Januel L, Laurencin C, Laut T, Lavillaureix A, Lesca G, Lesieur-Sebellin M, Magistrelli L, Marelli C, Mefford HC, Mendelsohn BA, Mercimek-Andrews S, Miller C, Mohammad SS, Morgante F, Nandipati S, Opladen T, Padmanaban M, Pauni M, Pezzoli G, Piton A, Ramond F, Riboldi GM, Rougeot-Jung C, Santos-Simarro F, Scheffer IE, Serari N, Stahl CM, Kung AS, Tarongí Sanchez S, Thauvin-Robinet C, Till M, Tranchant C, Troedson C, Tropea TF, Vanakker O, Vega P, Wiese ML, Wieshmann U, Williams LJ, Wirth T, Zech M, Zempel H, Roze E, Leuzzi V, Galosi S, Fung VSC, Carvill G, Krainc D, Gerard E, Mencacci NE. Brooker SM, et al. Ann Neurol. 2025 Sep;98(3):561-572. doi: 10.1002/ana.27272. Epub 2025 Jul 1. Ann Neurol. 2025. PMID: 40590478 Free PMC article.

References

    1. Pires AO, Teixeira FG, Mendes-Pinheiro B, Serra SC, Sousa N, Salgado AJ. Old and new challenges in Parkinson's disease therapeutics. Prog Neurobiol. (2017) 156:69–89. 10.1016/j.pneurobio.2017.04.006 - DOI - PubMed
    1. Kalia LV, Lang AE. Parkinson's disease. Lancet. (2015) 386:896–912. 10.1016/S0140-6736(14)61393-3 - DOI - PubMed
    1. Billingsley KJ, Bandres-Ciga S, Saez-Atienzar S, Singleton AB. Genetic risk factors in Parkinson's disease. Cell Tissue Res. (2018) 373:9–20. 10.1007/s00441-018-2817-y - DOI - PMC - PubMed
    1. Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem Sci. (2015) 40:200–10. 10.1016/j.tibs.2015.02.003 - DOI - PubMed
    1. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. (2016) 15:1257–72. 10.1016/S1474-4422(16)30230-7 - DOI - PubMed

LinkOut - more resources